アレルギー性鼻炎薬の世界市場2016-2020...市場調査レポートについてご紹介

【英文タイトル】Global Allergic Rhinitis Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview: Allergic rhinitis
• Understanding the disease
• Classification of allergic rhinitis
• Causes
• Signs and symptoms
• Risk factors
• Diagnosis and testing
• Treatment
• Epidemiology
• Economic burden and impact on quality of life

PART 06: Pipeline analysis
• Information on pipeline candidates
• Clinical trial information of allergic rhinitis

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation based on class of drugs
• Antihistamines
• Intranasal corticosteroids
• Immunotherapies
• Global antihistamines drugs market
• Global intranasal corticosteroids drugs market
• Global immunotherapies drugs market

PART 09: Market segmentation by route of administration
• Oral
• Parenteral
• Intranasal

PART 10: Market segmentation by dosage form
• Solid
• Liquid

PART 11: Geographical segmentation
• Global allergic rhinitis drugs market by geography 2015-2020
• Allergic rhinitis drugs market in Americas
• Allergic rhinitis drugs market in EMEA
• Allergic rhinitis drugs market in APAC

PART 12: Market drivers
• Increased prevalence of allergic rhinitis
• Rise in awareness about allergic rhinitis
• High usage of tobacco
• Presence of high unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges
• Increased preference for CAM
• Patent expiries and competition from generic drugs
• Adverse effects of drugs
• Poor patient adherence

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Self-medication using OTC products
• Increased R&D
• Intense competition
• Strategic alliances

PART 17: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• AstraZeneca
• GlaxoSmithKline
• Meda Pharmaceuticals
• Merck
• Sanofi
• UCB
• Other prominent vendors

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of allergic rhinitis
Exhibit 03: Risk factors associated with allergic rhinitis
Exhibit 04: Major diagnostic procedures for allergic rhinitis
Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Examples of non-pharmacological therapies
Exhibit 09: Treatment algorithm of allergic rhinitis
Exhibit 10: Prevalence of allergic rhinitis in China
Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio
Exhibit 12: Allergic rhinitis clinical trials by development phase 2015
Exhibit 13: Allergic rhinitis clinical trials by trial status 2015
Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Global allergic rhinitis market based on class of drugs
Exhibit 17: Examples of prescription and OTC intranasal corticosteroids
Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015
Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions)
Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions)
Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions)
Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions)
Exhibit 23: Global allergic rhinitis drugs market by route of administration
Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form
Exhibit 25: Global allergic rhinitis drugs market by geography 2015
Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Drivers of global allergic rhinitis drugs market
Exhibit 31: Impact of drivers
Exhibit 32: Challenges of global allergic rhinitis drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Trends of global allergic rhinitis drugs market
Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015
Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions)
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: AstraZeneca: Key takeaways
Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 46: GlaxoSmithKline: Key takeaways
Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014
Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 50: Meda Pharmaceuticals: Top-selling drugs
Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions)
Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions)
Exhibit 53: Meda Pharmaceuticals: Key takeaways
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Merck: Top-selling drugs
Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)
Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)
Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)
Exhibit 61: Merck: Key takeaways
Exhibit 62: Sanofi: Business segmentation by revenue 2014
Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 64: Sanofi: Geographical segmentation by revenue 2014
Exhibit 65: Sanofi: Top-selling drugs
Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions)
Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions)
Exhibit 69: Sanofi: Key takeaways
Exhibit 70: UCB: Product segmentation by revenue 2014
Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 72: UCB: Geographical segmentation by revenue 2014
Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions)
Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions)
Exhibit 75: UCB: Key takeaways


【レポート販売概要】

■ タイトル:アレルギー性鼻炎薬の世界市場2016-2020
■ 英文:Global Allergic Rhinitis Drugs Market 2016-2020
■ 発行日:2016年2月10日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8279
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。